Equities

3D Medicines Inc

3D Medicines Inc

Actions
  • Price (HKD)2.16
  • Today's Change-0.35 / -13.94%
  • Shares traded993.00k
  • 1 Year change-91.60%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments997942824
Total Receivables, Net8515672
Total Inventory4.611.200.01
Prepaid expenses8.974412
Other current assets, total--010
Total current assets1,0951,143919
Property, plant & equipment, net193178119
Goodwill, net------
Intangibles, net0.730.830.93
Long term investments124----
Note receivable - long term125.4617
Other long term assets3.913.363.69
Total assets1,4291,3321,060
LIABILITIES
Accounts payable72163.74
Accrued expenses122190119
Notes payable/short-term debt000
Current portion long-term debt/capital leases22511513
Other current liabilities, total82553,112
Total current liabilities5003763,248
Total long term debt586046
Total debt28217659
Deferred income tax------
Minority interest(66)(48)(35)
Other liabilities, total--039
Total liabilities4923893,298
SHAREHOLDERS EQUITY
Common stock0.230.220.06
Additional paid-in capital4,7854,228135
Retained earnings (accumulated deficit)(3849)(3285)(2373)
Treasury stock - common(0.01)(0.03)(0.03)
Unrealized gain (loss)------
Other equity, total------
Total equity937943(2238)
Total liabilities & shareholders' equity1,4291,3321,060
Total common shares outstanding25826256
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.